title: Treatment of tinnitus with gabapentin: a pilot study.
abstract: OBJECTIVE
  To evaluate the effectiveness of gabapentin (Neurontin) improve the disease-specific quality of life in patients with moderate tinnitus.
  
  
  METHODS
  Randomized, double blind, placebo-controlled clinical trial.
  
  
  METHODS
  Single-center academic outpatient otolaryngology practice.
  
  
  METHODS
  Gabapentin 1800 mg daily versus placebo.
  
  
  METHODS
  The study design is a randomized, double blind placebo controlled single site trial conducted in an academic medical center. Inclusion criteria included patients between ages 18 and 70 with a complaint of nonpulsatile, subjective tinnitus, bilateral or unilateral, greater than 3 months in duration. The primary outcome measure is the Tinnitus Handicap Inventory; secondary measures include the Profile of Mood States (POMS) rating scale, subjective tinnitus severity. The null hypothesis addressed in this study is that the drug would not result in significant alleviation of the symptom of tinnitus.
  
  
  RESULTS
  Seventy-six patients completed the trial; of these 52 received the drug. No significant differences were found between the two groups after 5 weeks of treatment with gabapentin.
  
  
  CONCLUSIONS
  There is insufficient evidence to support the effectiveness of gabapentin in the treatment of tinnitus.
authors.affiliation: Division of Otolaryngology, Head and Neck Surgery, Department of Surgery, Durham, North Carolina, USA. witse001@mc.duke.edu
authors.forename: David L
authors.initials: DL
authors.lastname: Witsell
authors.forename: Maureen T
authors.initials: MT
authors.lastname: Hannley
authors.forename: Sandra
authors.initials: S
authors.lastname: Stinnet
authors.forename: Debara L
authors.initials: DL
authors.lastname: Tucci
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000588:Amines / Q000627:therapeutic use*; D000700:Analgesics / Q000627:therapeutic use*; D001309:Auditory Threshold / Q000502:physiology; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D004185:Disability Evaluation; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D000077206:Gabapentin; D006312:Hearing Loss, Bilateral / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology; D046088:Hearing Loss, Unilateral / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D019964:Mood Disorders / Q000175:diagnosis / Q000453:epidemiology; D010865:Pilot Projects; D011788:Quality of Life / Q000523:psychology; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D014012:Tinnitus / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use*
chemical_list: D000588:Amines; D000700:Analgesics; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin